BIOMAT Database Logo BIOMAT Database Logo

Design and synthesis of 2-Substituted-4-benzyl-5-methylimidazoles as new potential Anti-breast cancer agents to inhibit oncogenic STAT3 functions. 2021

Botros Y Beshay, and Amira A Abdellatef, and Yasser M Loksha, and Salwa M Fahmy, and Nargues S Habib, and Alaa El-Din A Bekhit, and Paris E Georghiou, and Yoshihiro Hayakawa, and Adnan A Bekhit
Department of Pharmaceutical Chemistry, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport, Alexandria, Egypt.

STAT3 signaling is known to be associated with tumorigenesis and further cancer cell-intrinsic activation of STAT3 leads to altered regulation of several oncogenic processes. Given the importance of STAT3 in cancer development and progression particularly breast cancer, it is crucial to discover new chemical entities of STAT3 inhibitor to develop anti-breast cancer drug candidates. Herein, 4-benzyl-2-benzylthio-5-methyl-1H-imidazole (2a) and 4-benzyl-5-methyl-2-[(2,6-difluorobenzyl)thio]-1H-imidazole (2d) from a group of thirty imidazole-bearing compounds showed greater STAT3 inhibition than their lead compounds VS1 and the oxadiazole derivative MD77. Within all tested compounds, ten derivatives effectively inhibited the growth of the two tested breast cancer cells with IC50 values ranging from 6.66 to 26.02 µM. In addition, the most potent derivatives 2a and 2d inhibited the oncogenic function of STAT3 as seen in the inhibition of colony formation and IL-6 production of breast cancer cell lines. Modeling studies provided evidence for the possible interactions of the synthesized compounds with the key residues of the STAT3-SH2 domain. Collectively, our present study suggests 2-substituted-4-benzyl-5-methylimidazoles are a new class of anti-cancer drug candidates to inhibit oncogenic STAT3 function.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015850 Interleukin-6 A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS. Hepatocyte-Stimulating Factor,Hybridoma Growth Factor,IL-6,MGI-2,Myeloid Differentiation-Inducing Protein,Plasmacytoma Growth Factor,B Cell Stimulatory Factor-2,B-Cell Differentiation Factor,B-Cell Differentiation Factor-2,B-Cell Stimulatory Factor 2,B-Cell Stimulatory Factor-2,BSF-2,Differentiation Factor, B-Cell,Differentiation Factor-2, B-Cell,IFN-beta 2,IL6,Interferon beta-2,B Cell Differentiation Factor,B Cell Differentiation Factor 2,B Cell Stimulatory Factor 2,Differentiation Factor 2, B Cell,Differentiation Factor, B Cell,Differentiation-Inducing Protein, Myeloid,Growth Factor, Hybridoma,Growth Factor, Plasmacytoma,Hepatocyte Stimulating Factor,Interferon beta 2,Interleukin 6,Myeloid Differentiation Inducing Protein,beta-2, Interferon

Related Publications

Botros Y Beshay, and Amira A Abdellatef, and Yasser M Loksha, and Salwa M Fahmy, and Nargues S Habib, and Alaa El-Din A Bekhit, and Paris E Georghiou, and Yoshihiro Hayakawa, and Adnan A Bekhit
[Synthesis of alpha-substituted 4(5)-methoxymethyl-5(4)-methylimidazoles (author's transl)].
May 1977, Archiv der Pharmazie,
Botros Y Beshay, and Amira A Abdellatef, and Yasser M Loksha, and Salwa M Fahmy, and Nargues S Habib, and Alaa El-Din A Bekhit, and Paris E Georghiou, and Yoshihiro Hayakawa, and Adnan A Bekhit
New 1,2-diaryl-4-substituted-benzylidene-5-4H-imidazolone derivatives: Design, synthesis and biological evaluation as potential anti-inflammatory and analgesic agents.
June 2017, Bioorganic chemistry,
Botros Y Beshay, and Amira A Abdellatef, and Yasser M Loksha, and Salwa M Fahmy, and Nargues S Habib, and Alaa El-Din A Bekhit, and Paris E Georghiou, and Yoshihiro Hayakawa, and Adnan A Bekhit
Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents.
January 2009, Bioorganic & medicinal chemistry,
Botros Y Beshay, and Amira A Abdellatef, and Yasser M Loksha, and Salwa M Fahmy, and Nargues S Habib, and Alaa El-Din A Bekhit, and Paris E Georghiou, and Yoshihiro Hayakawa, and Adnan A Bekhit
Design, Synthesis and Evaluation of Novel N-Substituted-[Benzoylamino]-5-Ethyl-1,2,3,6-Tetrahydropyridines as Potential Anti-Cancer Agents.
January 2019, Madridge journal of pharmaceutical research,
Botros Y Beshay, and Amira A Abdellatef, and Yasser M Loksha, and Salwa M Fahmy, and Nargues S Habib, and Alaa El-Din A Bekhit, and Paris E Georghiou, and Yoshihiro Hayakawa, and Adnan A Bekhit
Design, synthesis and identification of novel substituted 2-amino thiazole analogues as potential anti-inflammatory agents targeting 5-lipoxygenase.
October 2018, European journal of medicinal chemistry,
Botros Y Beshay, and Amira A Abdellatef, and Yasser M Loksha, and Salwa M Fahmy, and Nargues S Habib, and Alaa El-Din A Bekhit, and Paris E Georghiou, and Yoshihiro Hayakawa, and Adnan A Bekhit
Design, synthesis, molecular docking, and in vitro studies of 2-mercaptoquinazolin-4(3H)-ones as potential anti-breast cancer agents.
March 2024, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society,
Botros Y Beshay, and Amira A Abdellatef, and Yasser M Loksha, and Salwa M Fahmy, and Nargues S Habib, and Alaa El-Din A Bekhit, and Paris E Georghiou, and Yoshihiro Hayakawa, and Adnan A Bekhit
Synthesis of N2-(substituted benzyl)-3-(4-methylphenyl)indazoles as novel anti-angiogenic agents.
January 2006, Bioorganic & medicinal chemistry,
Botros Y Beshay, and Amira A Abdellatef, and Yasser M Loksha, and Salwa M Fahmy, and Nargues S Habib, and Alaa El-Din A Bekhit, and Paris E Georghiou, and Yoshihiro Hayakawa, and Adnan A Bekhit
Synthesis and Biological Evaluation of 2-Substituted Benzyl-/Phenylethylamino-4-amino-5-aroylthiazoles as Apoptosis-Inducing Anticancer Agents.
May 2020, Molecules (Basel, Switzerland),
Botros Y Beshay, and Amira A Abdellatef, and Yasser M Loksha, and Salwa M Fahmy, and Nargues S Habib, and Alaa El-Din A Bekhit, and Paris E Georghiou, and Yoshihiro Hayakawa, and Adnan A Bekhit
Green Synthesis of Potential Antifungal Agents: 2-Benzyl Substituted Thiobenzoazoles.
November 2017, Journal of agricultural and food chemistry,
Botros Y Beshay, and Amira A Abdellatef, and Yasser M Loksha, and Salwa M Fahmy, and Nargues S Habib, and Alaa El-Din A Bekhit, and Paris E Georghiou, and Yoshihiro Hayakawa, and Adnan A Bekhit
Design and synthesis of new 2-substituted-5-[2-(2-halobenzyloxy)phenyl]-1,3,4-oxadiazoles as anticonvulsant agents.
April 2008, Chemical & pharmaceutical bulletin,
Copied contents to your clipboard!